“Success in the life sciences venture business is primarily driven by people - those you invest in and those you invest with.”  

Broad transaction experience and a wide network enable Scott to provide assistance to companies when raising capital, forming strategic partnerships and analyzing exit options.

Prior to joining Pappas Capital in 2006, Scott was an investment manager and research analyst for Silverback Asset Management’s life science fund, where he focused on healthcare securities investing. Before joining Silverback, he spent three years at Chicago Growth Partners focused on healthcare venture investments, and prior to that, he spent three and a half years in investment banking at Lehman Brothers where he worked in New York, London and Hong Kong.

Scott currently serves as a director for Milestone Pharmaceuticals, and as an observer for Envisia Therapeutics, IlluminOss Medical, Liquidia Technologies and Thrasos Therapeutics. He previously served as a director for Rotation Medical (acquired by Smith & Nephew), and as an observer for LipoScience (NASDAQ: LPDX) (acquired by LabCorp) and TESARO (NASDAQ: TSRO). Scott is also a member of the Investor Advisory Board of the Florida Institute for the Commercialization of Public Research, and a board member for the Council for Entrepreneurial Development (CED).


Duke University (BS in Biological Anthropology and Anatomy)
Duke University Fuqua School of Business (MBA)

In the News:

Scott will be participating in Johnson & Johnson Innovation's, JLABS "Meet With...Pappas Capital" event in New York on January 31, 2018


Serves as a Director for:
  • Milestone Pharmaceuticals, Inc.
Serves as an Observer for:
  • Envisia Therapeutics, Inc.
  • IlluminOss Medical, Inc.
  • Liquidia Technologies, Inc.
  • Thrasos Therapeutics, Inc.
  • Investor Advisory Board Member, Florida Institute for the Commercialization of Public Research
  • Board Member, Council for Entrepreneurial Development (CED)